Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

LANNETT COMPANY, INC. (LCI)
Mes dernières consult.
Most popular
Report
 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2018 659 M
EBIT 2018 218 M
Net income 2018 79,1 M
Debt 2018 -
Yield 2018 -
Sales 2019 675 M
EBIT 2019 218 M
Net income 2019 98,5 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 18,39
P/E ratio 2019 12,04
Capi. / Sales2018 1,39x
Capi. / Sales2019 1,35x
Capitalization 913 M
More Financials
Company
Lannett Co., Inc. engages in the development, manufacture, market, and distribution of generic pharmaceutical products.Its pharmaceutical products are distributed to drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers,... 
Sector
Pharmaceuticals
Calendar
11/09Earnings Release
More about the company
Surperformance© ratings of Lannett Company, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on LANNETT COMPANY, INC.
10/18 LANNETT : Generic Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma..
10/05 LANNETT : Board Of Directors Initiates CEO Search
10/05 LANNETT : Announces Dismissal Of Class Action Lawsuit
10/04 LANNETT : Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules U..
10/02 LANNETT : Receives Two FDA Approvals For Lansoprazole Delayed-Release Capsules U..
09/29 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Gets FDA Approval for Oxyc..
09/29 LANNETT : Receives FDA Approval for Oxycodone and Acetaminophen Tablets USP, 5 m..
09/28 LANNETT : Arthur Bedrosian, Lannett CEO, Prevails In Lawsuit With Internal Reven..
09/28 LANNETT : Receives Approval for Dexmethylphenidate Hydrochloride Tablets, 2.5 mg..
09/28 LANNETT : Announces Dismissal 0f Class Action Lawsuit
More news
Sector news : Pharmaceuticals - NEC
11:09pDJMERCK AND : to Lay Off About 1,800 U.S. Sales Reps in Cost-Cutting Move
06:45p MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
11:45aDJABBOTT LABORATORIES : Hacking Is a Risk for Pacemakers. So Is the Fix
10/19DJCELGENE : Halts Crohn's Disease Drug Trials
10/19DJEuropean Corporate Roundup for Thursday
More sector news : Pharmaceuticals - NEC
Income Statement Evolution
Consensus
 
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 23,0 $
Spread / Average Target -6,1%
EPS Revisions
Managers
NameTitle
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Kristin A. Arnold Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
LANNETT COMPANY, INC.874
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214